Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial (Q38792704)

From Wikidata

Jump to navigation Jump to search

scientific article published on May 2017

edit

Language	Label	Description	Also known as
English	Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial	scientific article published on May 2017

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

title

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial (English)

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

main subject

lung cancer

1 reference

based on heuristic

inferred from title

docetaxel

1 reference

based on heuristic

inferred from title

author

Fiona Blackhall

series ordinal

8

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

Pasi A Jänne

series ordinal

1

object named as

Pasi A Jänne

1 reference

stated in

Europe PubMed Central

retrieved

3 March 2018

PMC publication ID

5815037

Michel M van den Heuvel

series ordinal

2

object named as

Michel M van den Heuvel

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

author name string

Fabrice Barlesi

series ordinal

3

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

Manuel Cobo

series ordinal

4

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

Julien Mazieres

series ordinal

5

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

Lucio Crinò

series ordinal

6

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

Sergey Orlov

series ordinal

7

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

Juergen Wolf

series ordinal

9

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

Pilar Garrido

series ordinal

10

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

Artem Poltoratskiy

series ordinal

11

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

Gabriella Mariani

series ordinal

12

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

Dana Ghiorghiu

series ordinal

13

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

Elaine Kilgour

series ordinal

14

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

Paul Smith

series ordinal

15

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

Alexander Kohlmann

series ordinal

16

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

David J Carlile

series ordinal

17

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

David Lawrence

series ordinal

18

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

Karin Bowen

series ordinal

19

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

Johan Vansteenkiste

series ordinal

20

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

language of work or name

English

0 references

publication date

1 May 2017

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

published in

The Journal of the American Medical Association

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

volume

317

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

issue

18

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

page(s)

1844-1853

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

cites work

Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815037

retrieved

23 June 2018

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815037

retrieved

23 June 2018

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815037

retrieved

23 June 2018

Model free audit methodology for bias evaluation of tumour progression in oncology

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815037

retrieved

23 June 2018

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815037

retrieved

23 June 2018

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815037

retrieved

23 June 2018

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815037

retrieved

23 June 2018

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815037

retrieved

23 June 2018

Comprehensive molecular profiling of lung adenocarcinoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815037

retrieved

23 June 2018

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815037

retrieved

23 June 2018

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815037

retrieved

23 June 2018

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815037

retrieved

23 June 2018

Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815037

retrieved

23 June 2018

A comprehensive survey of Ras mutations in cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815037

retrieved

23 June 2018

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815037

retrieved

23 June 2018

Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815037

retrieved

23 June 2018

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815037

retrieved

23 June 2018

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815037

retrieved

23 June 2018

The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815037

retrieved

31 August 2018

LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815037

retrieved

31 August 2018

A recycling framework for the construction of Bonferroni-based multiple tests.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815037

retrieved

31 August 2018

Identifiers

DOI

10.1001/JAMA.2017.3438

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

PMC publication ID

5815037

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

PubMed publication ID

28492898

1 reference

stated in

Europe PubMed Central

PMC publication ID

5815037

retrieved

3 March 2018

reference URL

http://europepmc.org/abstract/PMC/5815037

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38792704&oldid=2065799609"